Alkem Laboratories Quarterly Results for Trading Insights
In Mar 2026, Alkem Laboratories (ALKEM) reported revenue ₹3,803 Cr and net profit ₹251 Cr — revenue +15.6% YoY. Analyse ALKEM promoter holding to track promoter, FII and institutional holdings.
ALKEM Quarterly Results — Revenue, Profit & EPS Highlights
Alkem Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View ALKEM 52-week chart for the annual high/low range and current price position.
- Revenue of ₹3,803 Cr in Mar 2026 (-2.3% vs Jun 2026, +15.6% vs Mar 2025)
- Net Profit of ₹251 Cr in Mar 2026 (-51.8% vs Jun 2026, -22.0% vs Mar 2025)
- EBITDA of ₹583 Cr in Mar 2026 (-36.6% vs Jun 2026)
- Operating Margin of 11.0% in Mar 2026 (-9.0pp vs Jun 2026)
- Earnings Per Share of ₹19.77 in Mar 2026 (-54.5% vs Jun 2026)
Alkem Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ALKEM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 3,803 | 3,893 | 4,105 | 3,290 | 3,521 | -2.3% | 15.6% |
| Net Profit (₹ Cr) | 251 | 521 | 779 | 322 | 668 | - | - |
| EBITDA (₹ Cr) | 583 | 919 | 1,025 | 537 | 889 | - | - |
| EPS (₹) | 19.77 | 43.49 | 63.99 | 25.57 | 55.56 | - | - |
| Operating Margin (%) | 11.0% | 20.0% | 23.0% | 12.0% | 22.0% | - | - |
ALKEM Share Price Trend — 1-Year Movement Across Quarterly Results
Alkem Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Alkem Laboratories screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ALKEM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Alkem Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores